Liver toxicity in epidemiological cohorts

Area of Science:

• Hepatology
• Infectious Diseases
• Pharmacology

Background:

• Antiretroviral therapy (ART) is crucial for managing human immunodeficiency virus type 1 (HIV-1) infection.
• Hepatotoxicity is a known adverse effect of ART, but previous studies lacked statistical power.
• The role of viral hepatitis coinfection in ART-induced hepatotoxicity requires further investigation.

Purpose of the Study:

• To investigate the association between ART and hepatotoxicity in a large patient cohort.
• To identify risk factors for ART-associated hepatotoxicity, including viral hepatitis coinfection and specific antiretroviral drugs.
• To assess the incidence and predictors of hepatotoxicity in HIV-1-infected patients.

Main Methods:

• Meta-analysis of data from four large studies: Amsterdam, CHORUS, ICONA, and Target, involving 5133 patients.
• Analysis of patient data to determine the incidence of hepatotoxicity.
• Statistical comparison of hepatotoxicity rates across different patient groups and drug regimens.

Main Results:

• Hepatotoxicity in HIV-1-infected patients was significantly associated with viral hepatitis coinfection across all analyzed cohorts.
• Elevated baseline alanine aminotransferase levels predicted subsequent hepatotoxicity in three of the cohorts.
• A low incidence of long-term hepatotoxicity was observed, with no consistent association with specific drug classes, except for nevirapine (within 12 weeks) and ritonavir, which were linked to increased risk.

Conclusions:

• Viral hepatitis coinfection is a significant risk factor for ART-associated hepatotoxicity.
• While overall long-term hepatotoxicity is low, early use of nevirapine and ritonavir use increase the risk.
• Hepatotoxicity risk management in HIV-1 patients should consider viral hepatitis status and specific drug choices.